Study of how children's bodies maintain tolerance to hemophilia A treatment
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This research examines why some children with hemophilia A can safely use a particular preventive medicine (called NFT) without their body developing resistance. Understanding these patterns may help doctors predict who will tolerate the treatment well and for how long.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with congenital hemophilia A (the inherited form, present from birth)
- Your child is currently receiving NFT (a type of preventive medicine) to prevent bleeding
- Your child is under 18 years old
- You or your child's guardian can provide written informed consent to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This study looks at using long-term blood thinners (anticoagulants) in adults with severe hemophilia A, a bleeding disorder. It aims to understand if this treatment can be safe and effective for patients who may need it.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.